Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

GNLX

Financials

Genelux Corporation

Notizie

Genelux prices public offering of 6.67 million shares at $3 each

Il titolo Genelux crolla dopo l’annuncio di una proposta di offerta pubblica

Genelux stock falls after announcing proposed public offering

Genelux announces proposed public offering of common stock

Genelux mantiene rating Buy da H.C. Wainwright grazie a dati promettenti nei trial sul cancro

Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data

Genelux nomina Jason Litten come direttore medico

Genelux appoints Jason Litten as chief medical officer

Il presidente di Genelux vende azioni GNLX per 66.000 dollari

Cappello, CTO di Genelux, vende azioni GNLX per 14.000 dollari

Il SVP di Genelux, Yu Yong, vende azioni per un valore di 16.000 dollari

Cappello, Genelux CTO, sells $14k in GNLX stock